SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 50 of 87
Word Count: 1498
Character Count: 9966

Document Content:

specializing in cardiovascular left atrial appendage devices. His previous tenure at BioVentrix, spanning from December 2021 to December 2023, included serving as Chief Operating Officer. Mr. Chartier was Vice President of Clinical Operations at Sirtex Medical from September 2020 to December 2021. Mr. Chartier has also held key positions at Cardiovascular Clinical Sciences (2019-2020), Anika Therapeutics (2017-2019), and InfraReDx (2007-2015), where he developed expertise in clinical operations, regulatory affairs, quality assurance, and manufacturing. Notably, at Anika Therapeutics, he was Vice President of Regulatory and Clinical Affairs, overseeing global regulatory strategies and clinical development for the company’s orthobiologics and regenerative medicine pipeline. Mr. Chartier began his career in clinical research and trial coordination at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Mr. Chartier earned a Bachelor of Arts in Psychology from Saint Anselm College in 1990 and obtained Regulatory Affairs Certification from the Regulatory Affairs Professional Society in 2003.

Ori Ben-Yehuda has been our Chief Medical Officer since January 2024 and is a distinguished clinical cardiologist and
clinical trialist with over 25 years of experience in treating patients with coronary disease, myocardial infarction, and heart failure.
In addition to his role at BioVentrix, Dr. Ben-Yehuda is a Professor of Medicine at the University of California, San Diego (UCSD), where
he leads the Cardiovascular Outcomes Group at the Sulpizio Cardiovascular Institute. Dr. Ben-Yehuda also holds editorial positions as
Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team. Dr. Ben-Yehuda’s
previous roles include Executive Director of the Clinical Trials Center at the Cardiovascular Research Foundation and Vice President
of Cardiovascular Clinical Trials at Gilead Sciences. Dr. Ben-Yehuda has authored and co-authored over 200 peer-reviewed publications
and has been recognized with multiple awards, including Top Abstract at the TCT Conference in 2017 and the Sackler Faculty Prize for
Excellence for his MD thesis. Dr. Ben-Yehuda earned his medical degree from the Sackler School of Medicine at Tel Aviv University in
Israel and completed a cardiovascular medicine fellowship at UCSD.

Director
Nominees

Mark
H. Ravich will serve as a director following the consummation of this offering. Since June 2017, Mr. Ravich has been a director
of Rockwell Medical (Nasdaq: RMTI), a pharmaceutical company, and is currently a member of its audit committee. Mr. Ravich also currently
serves as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded
in 1998. From October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer
of medical imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich previously served as a director of BioVentrix.
Previously, from February 2013 to 2018, Mr. Ravich served as a director of Orchids Paper Products Company, a national supplier of high-quality
consumer tissue products, as well as chairman of its governance committee and as a member of its audit committee. Orchids Paper Products
Company filed for Chapter 11 bankruptcy on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware. From June 2004 to
2018, Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency
coils. From 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International,
Inc., a wholesale retail company, where he also led its initial public offering. From 1978 to 1990, Mr. Ravich was a developer of commercial
real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various
commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank
N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also is the chief manager of various
real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and
an M.B.A. degree with a major in finance. We believe that Mr. Ravich’s extensive board experience across the pharmaceutical, medical
device, and real estate sectors, combined with his financial expertise and leadership in both public and private companies qualifies
him to be a member of our board of directors.

Rishi Puri, MD, PhD, FRACP, FACC will serve as a director following the consummation of this offering. Dr. Puri is a
coronary and structural interventional cardiologist at the Cleveland Clinic. He is also an Associate Professor of Medicine and
Medical Director of the Angiography & IVUS Core Laboratory. He also currently serves as Chief Medical Director of T45 Labs, a
Bay Area medical device incubator. He completed his clinical and academic training in Adelaide (Sth Australia), Cleveland (USA),
Quebec City (Canada), Rennes (France), and Zurich (Switzerland). Dr. Puri has published over 450 original manuscripts in high-impact
journals across a broad topic base including transcatheter structural heart interventions for valvular heart disease and heart
failure, atherosclerosis progression-regression and plaque imaging, and coronary physiology/pharmacology. He is actively involved in
developing novel device-based technologies in the coronary, structural heart disease and interventional heart failure spaces, has
co-founded and advises a range of medical start-up companies and larger strategics. He currently serves as global co-PI for the
TRICAV-1 and TRICAV-2 FDA pivotal trial testing a bi-caval stenting system for patients with severe TR, the ADVANCE-DCB FIM trial of
a dual API nanoparticle drug-eluting balloon in de novo coronary lesions, is the US national co-PI for the ALLAY-HFrEF trial.
He also serves on the global steering committees of a range of other pivotal trials in the aortic and mitral valve therapy space.
Dr. Puri graduated from the University of Adelaide with an MBBS (MD) degree and later received his PhD from the University of
Adelaide. Dr. Puri also received an FRACP degree from the Royal Australasian College of Physicians. We believe that Dr. Puri’s extensive clinical, academic, and device development experience qualifies him to
be a member of our board of directors.

William Abraham will serve as a director following the consummation of this offering. Dr. Abraham has participated as a site
Principal Investigator in more than 100 multicenter clinical drug and device trials, serving as national or international Principal
Investigator and/or on the Executive or Steering Committees of more than 50 multicenter trials. He was the lead author on the
landmark MIRACLE clinical trial for cardiac resynchronization therapy published in 2002, a lead Principal Investigator (PI) for the
CHAMPION implantable hemodynamic monitoring trial published in 2011, and one of the lead PIs for the recently published COAPT trial
studying percutaneous mitral valve repair. He has participated in all regulatory phases of new device development from pre-clinical
assessment through FDA Pre-Market Approval (PMA) submission and approval. He has authored more than 1,000 original research
manuscripts and other papers, and has been published in high impact journals, including The New England Journal of Medicine, The
Lancet, and the Journal of the American Medical Association. We believe that Dr. Abraham’s clinical-trial leadership, academic expertise, regulatory experience, and board
service at other public life sciences companies qualify him to serve as a member of our board of directors.

Family
Relationships

There
are no family relationships between or among any of the current directors, executive officers or persons nominated or charged to become
directors or executive officers.

Number
and Terms of Office of Officers and Directors

Our
business and affairs are organized under the direction of our board of directors. Upon the consummation of this offering, our board of
directors will consist of five directors, including two executive directors and three independent directors.

Our
Amended and Restated Bylaws provide that the number of directors will be fixed by the board of directors within a range of between 1
and 9 directors. The directors need not be stockholders unless so required by our certificate of incorporation. The minimum or maximum
number may be increased or decreased from time to time only by an amendment to the bylaws, which power belongs exclusively to our board
of directors.

Our
officers are appointed by the board of directors and shall hold office at the discretion of the board of directors until their successors
are duly elected and qualified, unless sooner removed. Our board of directors is authorized to appoint officers to the offices set forth
in our bylaws.

Director
Independence

The
Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined
generally as a person who has no material relationship with the listed company (either directly or as a partner, shareholder or officer
of an organization that has a relationship with our company). We have three “independent directors” as defined in the Nasdaq
listing standards and applicable SEC rules prior to completion of this offering.

Our
board has determined that Mark Ravich, Rishi Puri and William Abraham are independent directors under applicable SEC and Nasdaq
rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.

Board
Committees